Piper Sandler Forecasts Strong Price Appreciation for Envista (NYSE:NVST) Stock

Envista (NYSE:NVST) had its price objective lifted by Piper Sandler from $17.00 to $18.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Piper Sandler’s price target would suggest a potential downside of 10.56% from the company’s previous close.

Several other research analysts also recently commented on the stock. Mizuho started coverage on shares of Envista in a research note on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target on the stock. Leerink Partnrs upgraded shares of Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Wells Fargo & Company started coverage on shares of Envista in a research note on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 price target for the company. Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and raised their price objective for the company from $16.00 to $23.00 in a research note on Thursday, October 31st. Finally, Jefferies Financial Group increased their target price on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.21.

Envista Stock Performance

Shares of NYSE NVST opened at $20.13 on Monday. The stock’s 50-day moving average is $20.04 and its 200 day moving average is $19.07. The stock has a market cap of $3.46 billion, a price-to-earnings ratio of -2.59, a P/E/G ratio of 1.82 and a beta of 1.34. Envista has a 1-year low of $15.15 and a 1-year high of $24.79. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42.

Institutional Trading of Envista

Several large investors have recently added to or reduced their stakes in NVST. Creative Planning lifted its position in shares of Envista by 116.5% in the 2nd quarter. Creative Planning now owns 24,246 shares of the company’s stock worth $403,000 after purchasing an additional 13,047 shares during the period. Handelsbanken Fonder AB increased its position in shares of Envista by 24.3% during the third quarter. Handelsbanken Fonder AB now owns 49,100 shares of the company’s stock valued at $970,000 after buying an additional 9,600 shares during the period. GAMMA Investing LLC raised its stake in Envista by 69.8% in the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares in the last quarter. Marathon Asset Management Ltd lifted its holdings in Envista by 2.4% in the third quarter. Marathon Asset Management Ltd now owns 1,136,350 shares of the company’s stock worth $22,454,000 after buying an additional 26,453 shares during the period. Finally, Blue Trust Inc. boosted its position in Envista by 69.7% during the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.